Personalized cancer treatments based on testing drugs quickly leads to faster treatment, better outcomes 
What your sad desk sandwich says about your working habits 
Eating some chocolate really might be good for you – here’s what the research says 
Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options 
Snakebites: we thought we’d created a winning new antivenom but then it flopped. Why that turned out to be a good thing 
Honey is said to help with hay fever symptoms – here’s what the research says about this claim 
Study links microplastics with human health problems – but there’s still a lot we don’t know 
Child health is in crisis in the UK – here’s what needs to change 
Online wellness content: 3 ways to tell evidence-based health information from pseudoscience 
How to look after your mental health while packing up Mum or Dad’s home 
The hidden racist history of hair loss 
Surgery won’t fix my chronic back pain, so what will? 
Elon Musk says ketamine can get you out of a ‘negative frame of mind’. What does the research say? 
Tapeworm larvae found in man’s brain – how did they get there? 
Proteins in milk and blood could one day let doctors detect breast cancer earlier – and save lives 
Gut microbiome: meet Roseburia intestinalis — the energy-producing bacterium that helps us fight against disease 
The search and development for a cure for HIV/AIDS continues, but thanks to today’s technological innovations, we become one step closer to developing a cure for all stages. Cuba makes a breakthrough in its HIV/AIDS vaccine project while organizations such as the Gates Foundation and NIH make donations for further testing and research.
Cuba has made some progress in its HIV/AIDS vaccine project. Referred to as “Teravac-HIV,” the scientists concluded their preclinical studies. They used lab animals and 20 human volunteers, and according to the leaders of this project, the results came out favorable. There were no adverse effects on the lab animals and in the volunteers.
The objective of Teravac-HIV is to induce an anti-HIV response within the body at a cellular level. This is to decrease the burden on patients who are suffering or are diagnosed with the disease through a “functional cure.”
Enrique Iglesias, the principal project specialist of Teravac-HIV stated that while cases of HIV/AIDS in Cuba is relatively low, there is still a high resistance to a few antiviral compounds that they use. Iglesias went on to say that a “therapeutic vaccine could contribute to the management of the epidemic.”
Meanwhile, scientists at the Fred Hutchinson Cancer Research Center in Seattle have received funding from the Gates Foundation and the National Institutes of Health that will go towards further testing and research. Even though there is a medication that can help manage the disease in over 24 million patients, missing a day or two can bring a relapse in the condition. Both organizations pledged over $100 million in grants that will support the gene-based research the scientists in the center are doing.
The scientists believe that the virus can eventually be “scrubbed out” of the bodies of those diagnosed through giving the blood cells “protective genes” or gene therapy. They hope that once this vaccine is fully realized and developed, they can spread this cure to all parts of the world.
Along with HIV/AIDS, the organizations, as well as the Center, hope that the grants can be used to further a cure for Sickle Cell disease, which is very prevalent in regions of Africa.
